Skip to main content

Table 1 Target and/or mechanism of drugs tested on genetic rodent models of ASD which are FDA approved or in clinical trials for any clinical disorder

From: A multifaceted approach for analyzing complex phenotypic data in rodent models of autism

Agent Target/mechanism References Clinical trials in ASD
IGF-1 Agonist: receptor kinase(tyrosine), Akt, IGF-1(receptor), insulin (receptor) [40] Yes, 2
Amphetamine Agonist: dopamine(receptor), norepinephrine(receptor), glutamate (ionotropic receptor NMDA), serotonin(receptor) [41] Yes, 1 (with ADHD)
Minocycline Neuroprotective, antibacterial and anti-inflammatory agent; inhibits: Tnf-alpha, nitric oxide synthase [42] Yes, 1
D-cycloserine Agonist: glutamate (ionotropic receptor NMDA) [43] Yes, 1
Vasopressin Agonist or upregulation: avp (receptor 1a/1b/2), autophagy, PIP pathway [44] Yes, ~ 3
Memantine Antagonist: glutamate (ionotropic receptor NMDA), serotonin (receptor 5-HT3), acetylcholine (nicotinic receptor); agonist: sigmaergic (receptor 1), dopamine (receptor D2) [45] Yes, ~ 10
Baclofen Agonist: gaba (receptor B) [46] Yes, ~ 8 (arbaclofen)
Risperidone Antagonist: dopamine (receptor D1/D5/D2/D3/D4), serotonin(receptors(5-HT2a/2c), adrenergic (receptor alpha1/alpha2), histamine (receptor H1) [47] Yes, ~ 7
Oxytocin Agonist: oxytocin(receptor) [48] Yes, ~ 24
  1. Clinical trial information was obtained from